Showing 1961-1970 of 2165 results for "".
- Bausch + Lomb Will Present Scientific Data and Analyses During World Cornea Congresshttps://modernod.com/news/bausch-lomb-will-present-scientific-data-and-analyses-during-world-cornea-congress/2481119/Bausch + Lomb announced the presentation of one podium and two poster presentations at the World Cornea Congress VIII meeting, which will take place in Chicago from September 28-29, 2022. 'The podium presentation will feature findings from the pivotal p
- Oyster Point's Tyrvaya To Be Covered By the Largest Medicare Pharmacy Benefit Managerhttps://modernod.com/news/oyster-point-pharma-announces-tyrvana-to-be-covered-by-the-largest-medicare-pharmacy-benefit-manager/2481032/Oyster Point Pharma announced that the largest Medicare Pharmacy Benefit Manager in the United States will add Tyrvaya Nasal Spray on its Medicare Part D formularies, effective September 1, 2022. “We are excited to announce this important milestone which will further expand p
- Aerie Pharmaceuticals Announces First Patient Dosed in the COMET-3 Study of AR-15512 for the Treatment of Dry Eye Diseasehttps://modernod.com/news/aerie-pharmaceuticals-announces-first-participant-dosed-in-the-comet-3-study-of-ar-15512-for-the-treatment-of-dry-eye-disease/2481006/Aerie Pharmaceuticals announced that the first participant has been dosed in the phase 3 registrational “COMET-3” study to evaluate AR-15512 ophthalmic solution as a treatment for the signs and symptoms of dry eye disease (DED). COMET-3 is the second of three trials in the p
- RD Fund Announces New Chair and Expansion of Board of Directorshttps://modernod.com/news/rd-fund-announces-new-chair-and-expansion-of-board-of-directors/2480990/The RD Fund (Retinal Degeneration Fund)—the venture arm of the Foundation Fighting Blindness aimed at driving research toward preventions, treatments, and cures for the entire spectrum of retinal degenerative diseases—announced the appointment of Adrienne Graves, P
- Nicox Granted New Patent for NCX 4251 in Japanhttps://modernod.com/news/nicox-granted-new-patent-for-ncx-4251-in-japan/2480657/Nicox SA announced that the Japanese Patent Office has granted a new patent expiring in 2040 covering the company’s product candidate NCX 4251. Patent JP.7021301 covers ophthalmic suspensions comprising a specific form of fluticasone p
- Aldeyra Therapeutics to Modify Phase 3 TRANQUILITY -2 Trial in Dry Eye Disease After Missing Primary Endpointhttps://modernod.com/news/aldeyra-therapeutics-to-modify-phase-3-tranquility-trial-in-dry-eye-disease-after-missing-primary-endpoint/2480528/Aldeyra Therapeutics announced topline results from the Phase 3 TRANQUILITY trial of it investigational dry eye drug reproxalap. The primary endpoint of ocular redness was not met in TRANQUILITY, according to a company news release. However, statistical significance (P=0.0001) was
- Clearside Biomedical Features FDA-Approved Xipere in Multiple Presentations at AAO and American Uveitis Society Meetingshttps://modernod.com/news/clearside-biomedical-features-fda-approved-xipere-in-multiple-presentations-at-aao-and-american-uveitis-society-meetings/2480454/Clearside Biomedical announced that multiple presentations were given at the American Academy of Ophthalmology (AAO) 2021, which took place November 12-15, 2021 in New Orleans, LA. “Our presentations at AAO and AUS, combined with the positive data p
- Glaukos Featured in Numerous Scientific Abstracts at 2021 ESCRShttps://modernod.com/news/glaukos-featured-in-numerous-scientific-abstracts-at-2021-escrs/2480335/Glaukos announced that its technologies will be featured in various scientific programming at the European Society of Cataract and Refractive Surgeons (ESCRS) annual meeting, being held October 8-11, 2021, in Amsterdam, Netherlands. Key Glaucoma Presentations: P
- Aerie Pharmaceuticals Announces the Appointment of Interim Executive Chair and Departure of Chairman and CEOhttps://modernod.com/news/aerie-pharmaceuticals-announces-the-appointment-of-interim-executive-chair-and-departure-of-chairman-and-ceo/2480293/Aerie Pharmaceuticals announced that it is executing its succession plan and that effective September 17, 2021, Vicente Anido, PhD, no longer serves as the company’s Chairman and Chief Executive Officer or as a director of the company. Consistent with the succession plan in p
- Oxurion to Present Clinical and Preclinical Data at Upcoming Euretina 2021 Virtual Congresshttps://modernod.com/news/oxurion-to-present-clinical-and-preclinical-data-at-upcoming-euretina-2021-virtual-congress/2479493/Oxurion NV will be presenting preclinical and clinical data from its ongoing development programs, THR-149 and THR-687, as novel treatments for diabetic macular edema (DME) at the Euretina 2021 virtual congress. The upcoming annual meeting of the European Society of Retina Specialists is taking p